Other studies have analyzed the urine levels of AQP5 and AQP2 excreted by exosomes in 35 patients with diabetes, suggesting that exosomal AQP5 and AQP2 may be used as novel noninvasive biomarkers to help classify the clinical stages of DN [51]. This evidence concerns the gene AQP5 and diabetes mellitus.